Revelation Biosciences, Inc. REVBW

Full chart Compare
Set alert

Price alert · REVBW

All alert types
0.00 USD 0.00 (-17.54%)

Nov 3, 2026, 12:47 PM EST

0.0034 Day range 0.0048
0.0034 52-week range 0.0048
YTD
-2.08%
1 year
-2.08%
Market cap
31.40K
EPS (ttm)
-4.77
YTD return
-2.08%
1-year return
-2.08%
Volume
25.50K
Open
0.0125
Previous close
0.0057
Day's range
0.0034 – 0.0048
52-week range
0.0034 – 0.0048

2Y 0.0000 (0.00%)

No chart data for this range yet.

Key statistics

Enterprise value
0
PEG ratio
0.00
Price / sales
0.00
Price / book
0.01
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
-6.49M
Total cash
6.54M
Total debt
0
Return on equity
-270.02%
Short % of float
0.00%
50-day average
0.00
200-day average
0.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on REVBW — it syncs with the Stock Master app.

Institution ownership

REVBW institution ownership
Holder% heldSharesValueReported
Linden Advisors LP10.46%338,1102.23KSep 29, 2024
Yakira Capital Management, Inc.7.64%246,8841.63KSep 29, 2024
Walleye Capital LLC5.78%187,0011.23KSep 29, 2024
Pine Valley Investments Ltd Liability Co.4.40%142,148938Sep 29, 2024
Walleye Trading LLC3.25%104,990692Sep 29, 2024
Cowen and Company, LLC3.09%99,900659Sep 29, 2024